UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 21, 2010
NURX
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
0-26694
|
87-0681500
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
c/o
ProElite, Inc.
12121
Wilshire Boulevard, Suite 1001
Los
Angeles, CA 90025
(Address
of principal executive offices) (Zip Code)
Registrant’s telephone number,
including area code: (949) 336-7111
Not
applicable
(Former
name or former address if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 1.02 Termination
of a Material Definitive Agreement.
On
December 21, 2010, the employment agreement dated as of September 21, 2007, by
and between the NuRx Pharmaceuticals, Inc. (the “Company”) and Steven Gershick
was terminated by the mutual agreement of the Company and Mr.
Gershick. Mr. Gershick had served as Chief Financial Officer and
Secretary of the Company. A copy of the employment agreement was previously
filed as Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the
Securities and Exchange Commission on September 20, 2007.
Item
5.02 Departure of Directors or Certain Officers.
As
discussed under Item 1.02 above, effective December 21, 2010, the employment of
Steven Gershick was terminated. Mr. Gershick had served as Chief
Financial Officer and Secretary of the Company.
On
December 21, 2010, Dr. Carl LeBel resigned as Executive Chairman of the
Company’s Board of Directors to pursue other opportunities. Dr. LeBel
was a member of the Nominating Committee.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
NURX
PHARMACEUTICALS, INC.
|
|||
Dated: December
23, 2010
|
By:
|
/s/ Harin Padma-Nathan | |
Name:
Dr. Harin Padma-Nathan
|
|||
Title:
President and Chief Executive Officer
|
|||